Cargando…
Examination of the Evidence for Off-Label Use of Gabapentin
OBJECTIVES: (1) Describe the relevance of off-label use of gabapentin to managed care pharmacy; (2) summarize recent FDA warnings and media reports related to off-label gabapentin use; (3) review medical information pertaining to the off-label use of gabapentin; (4) outline alternatives to off-label...
Autor principal: | Mack, Alicia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437292/ https://www.ncbi.nlm.nih.gov/pubmed/14664664 http://dx.doi.org/10.18553/jmcp.2003.9.6.559 |
Ejemplares similares
-
Impact of a Clinical Pharmacy Consult Service on Guideline Adherence and Management of Gabapentin for Neuropathic Pain
por: Winterbottom, Lisa M., et al.
Publicado: (2006) -
Examination of Multiple Medication Use Among TRICARE Beneficiaries Aged 65 Years and Older
por: Linton, Andrea, et al.
Publicado: (2007) -
An Early Examination of Access to Select Orphan Drugs Treating Rare Diseases in Health Insurance Exchange Plans
por: Robinson, Sandy W., et al.
Publicado: (2014) -
Gabapentin for Off-Label Use: Evidence-Based or Cause for Concern?
por: Peckham, Alyssa M, et al.
Publicado: (2018) -
Opioid Drug Utilization and Cost Outcomes Associated With the Use of Buprenorphine-Naloxone in Patients With a History of Prescription Opioid Use
por: Kaur, Aman Deep, et al.
Publicado: (2008)